vs
Side-by-side financial comparison of BARFRESH FOOD GROUP INC. (BRFH) and Immunovant, Inc. (IMVT). Click either name above to swap in a different company.
Immunovant, Inc. is the larger business by last-quarter revenue ($8.4M vs $5.4M, roughly 1.5× BARFRESH FOOD GROUP INC.). BARFRESH FOOD GROUP INC. runs the higher net margin — -14.1% vs -899.0%, a 884.9% gap on every dollar of revenue. On growth, Immunovant, Inc. posted the faster year-over-year revenue change (140.7% vs 94.5%). BARFRESH FOOD GROUP INC. produced more free cash flow last quarter ($426.0K vs $-59.8M).
Barfresh Food Group Inc. is a specialized food and beverage firm that develops, manufactures, and distributes frozen ready-to-blend smoothies, frappes, and related beverage products. Its core client base includes quick service restaurants, K-12 schools, healthcare facilities, and hospitality operators across North America, delivering portion-controlled, easy-to-prepare solutions that cut down on front-of-house preparation work for food service partners.
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody therapies for patients with serious, rare autoimmune and inflammatory diseases. Its lead product candidate covers multiple autoimmune indications, with core U.S. operations and a global market expansion strategy.
BRFH vs IMVT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $5.4M | $8.4M |
| Net Profit | $-763.0K | $-75.3M |
| Gross Margin | 2.9% | — |
| Operating Margin | -28.9% | -896.2% |
| Net Margin | -14.1% | -899.0% |
| Revenue YoY | 94.5% | 140.7% |
| Net Profit YoY | 10.4% | -26.7% |
| EPS (diluted) | $-0.04 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $5.4M | — | ||
| Q3 25 | $4.2M | — | ||
| Q2 25 | $1.6M | — | ||
| Q1 25 | $2.9M | — | ||
| Q4 24 | $2.8M | — | ||
| Q3 24 | $3.6M | — | ||
| Q2 24 | $1.5M | — | ||
| Q1 24 | $2.8M | $8.4M |
| Q4 25 | $-763.0K | — | ||
| Q3 25 | $-290.0K | — | ||
| Q2 25 | $-880.0K | — | ||
| Q1 25 | $-761.0K | — | ||
| Q4 24 | $-852.0K | — | ||
| Q3 24 | $-513.0K | — | ||
| Q2 24 | $-1.0M | — | ||
| Q1 24 | $-449.0K | $-75.3M |
| Q4 25 | 2.9% | — | ||
| Q3 25 | 36.7% | — | ||
| Q2 25 | 31.1% | — | ||
| Q1 25 | 30.7% | — | ||
| Q4 24 | 26.2% | — | ||
| Q3 24 | 34.6% | — | ||
| Q2 24 | 34.8% | — | ||
| Q1 24 | 41.4% | — |
| Q4 25 | -28.9% | — | ||
| Q3 25 | -6.1% | — | ||
| Q2 25 | -53.4% | — | ||
| Q1 25 | -25.2% | — | ||
| Q4 24 | -29.5% | — | ||
| Q3 24 | -13.7% | — | ||
| Q2 24 | -68.6% | — | ||
| Q1 24 | -15.8% | -896.2% |
| Q4 25 | -14.1% | — | ||
| Q3 25 | -6.9% | — | ||
| Q2 25 | -54.2% | — | ||
| Q1 25 | -26.0% | — | ||
| Q4 24 | -30.6% | — | ||
| Q3 24 | -14.1% | — | ||
| Q2 24 | -69.1% | — | ||
| Q1 24 | -15.9% | -899.0% |
| Q4 25 | $-0.04 | — | ||
| Q3 25 | $-0.02 | — | ||
| Q2 25 | $-0.06 | — | ||
| Q1 25 | $-0.05 | — | ||
| Q4 24 | $-0.06 | — | ||
| Q3 24 | $-0.03 | — | ||
| Q2 24 | $-0.07 | — | ||
| Q1 24 | $-0.03 | $-0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $635.4M |
| Total DebtLower is stronger | $766.0K | — |
| Stockholders' EquityBook value | $1.3M | $617.8M |
| Total Assets | $12.8M | $666.4M |
| Debt / EquityLower = less leverage | 0.58× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $1.2M | $635.4M |
| Q4 25 | $766.0K | — | ||
| Q3 25 | $596.0K | — | ||
| Q2 25 | $176.0K | — | ||
| Q1 25 | $200.0K | — | ||
| Q4 24 | $223.0K | — | ||
| Q3 24 | $246.0K | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.3M | — | ||
| Q3 25 | $1.9M | — | ||
| Q2 25 | $2.0M | — | ||
| Q1 25 | $2.8M | — | ||
| Q4 24 | $578.0K | — | ||
| Q3 24 | $1.4M | — | ||
| Q2 24 | $1.7M | — | ||
| Q1 24 | $2.5M | $617.8M |
| Q4 25 | $12.8M | — | ||
| Q3 25 | $6.8M | — | ||
| Q2 25 | $3.8M | — | ||
| Q1 25 | $5.3M | — | ||
| Q4 24 | $3.3M | — | ||
| Q3 24 | $3.8M | — | ||
| Q2 24 | $3.3M | — | ||
| Q1 24 | $4.7M | $666.4M |
| Q4 25 | 0.58× | — | ||
| Q3 25 | 0.31× | — | ||
| Q2 25 | 0.09× | — | ||
| Q1 25 | 0.07× | — | ||
| Q4 24 | 0.39× | — | ||
| Q3 24 | 0.18× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $507.0K | $-59.7M |
| Free Cash FlowOCF − Capex | $426.0K | $-59.8M |
| FCF MarginFCF / Revenue | 7.9% | -714.4% |
| Capex IntensityCapex / Revenue | 1.5% | 1.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-1.9M | $-214.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $507.0K | — | ||
| Q3 25 | $-598.0K | — | ||
| Q2 25 | $-1.1M | — | ||
| Q1 25 | $-506.0K | — | ||
| Q4 24 | $-685.0K | — | ||
| Q3 24 | $5.0K | — | ||
| Q2 24 | $-780.0K | — | ||
| Q1 24 | $-769.0K | $-59.7M |
| Q4 25 | $426.0K | — | ||
| Q3 25 | $-650.0K | — | ||
| Q2 25 | $-1.1M | — | ||
| Q1 25 | $-534.0K | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-52.0K | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-59.8M |
| Q4 25 | 7.9% | — | ||
| Q3 25 | -15.4% | — | ||
| Q2 25 | -69.8% | — | ||
| Q1 25 | -18.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1.4% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -714.4% |
| Q4 25 | 1.5% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 4.1% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.8% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BRFH
| Raw And Processed Milk | $2.7M | 51% |
| Other | $2.7M | 49% |
IMVT
Segment breakdown not available.
